分享好友 资讯首页 频道列表

Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 20281 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 2030

2026-09-30 15:3517430

COURBEVOIE, France--(BUSINESS WIRE)--Bureau Veritas (BOURSE:BVI):

CAPITAL MARKETS DAY 2026

Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution.

› 2024-2026 achievements:

  • Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3;
  • Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit;
  • New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company;
  • Driving growth and profitability: through Portfolio management for leadership, modernizing to maximize Performance, and taking an Expert First approach to People;

› LEAP | 28 guidance update: confirming all ambitions for 2028 and updating the following:

  • Total revenue CAGR1 upgraded to double-digit (from high-single digit) for 2027 – 2028,
  • Leverage range narrowed to 1.5x to 2.0x (from 1.0 to 2.0x)

› AI as a growth catalyst: one governing framework to deploy AI across operations, with a target of EUR1 billion in AI-driven markets and services revenue by 2030.

Hinda Gharbi, Chief Executive Officer, commented:

"Bureau Veritas has successfully executed on its commitments since launching LEAP | 28 in March 2024. We have achieved strong organic growth, improved margins and generated attractive shareholder returns, while navigating a complex macroeconomic environment.

I would like to thank our colleagues around the world for their engagement and their hard work.

Today we confirm our 2028 ambition and move into the next phase of our strategy execution. We have rotated more than a fifth of our portfolio and we now operate under a new Product Line-centric operating model as a multi-specialist Company. We have simplified our growth algorithm by reorganizing into 4 divisions and 10 Product Lines.

In line with our LEAP | 28 plan, we have deployed performance programs that have already delivered 110 basis points of margin improvement. On the People front, we have implemented new capability development programs supporting new strongholds growth.

In 2027 and 2028, we will accelerate acquisitions, and we will complete the full rollout of the performance and people programs and amplify their impact.

AI is a transformative technology that creates multiple opportunities for Bureau Veritas. We will continue to integrate it broadly into our strategic programs. Our ambition is to generate EUR 1 billion in revenue from AI-driven markets and services by 2030.

The first phase of LEAP | 28 execution confirms the effectiveness of our strategy, allowing us to accelerate as we deliver on our ambition and prepare for an increased performance beyond 2028.”

LEAP | 28 STRATEGY UPDATE

In 2024, Bureau Veritas introduced its unified vision to be the preferred partner for customers’ excellence and sustainability. The strategic framework was launched at the same time and centered under three pillars Portfolio, Performance, and People, with sustainability at its core.

Portfolio: active management and accelerated rotation

Since the launch of LEAP | 28, the Company has rotated c. 21% of its portfolio, completing 24 acquisitions representing approximately EUR 413 million of annualized revenue. It also completed three divestments and is finalizing one exit and one divestment, totaling approximately EUR 837 million of annualized revenue.

Bureau Veritas classified its portfolio into three streams: Expand Leadership, New Strongholds, and Optimize Value and Impact.

Business included in Expand Leadership and New Strongholds now account for approximately 68% of Company revenue (FY 2026 estimate), up from 55% at the start of the plan.

For 2027–2028, M&A will accelerate and focus on delivering accretive revenue growth and margins to business divisions.

Sustainability ambition

The sustainability drive observed in 2024 continues with organizations managing risks and protecting their brands, reputations, and competitive advantages. The greening of the economy is accelerating, and we are growing our services in support of green objects in various industries. Bureau Veritas’ ambition to reach c.15% of Company revenue in 2028 through organic and M&A contribution is on track. The Company achieved c.8% at the end of the first half of 2026 from c.5% in 2023.

New operating model

The Company has evolved its operating model from 6 reporting lines and 21 sub-segments into 4 divisions. The divisions are Industrials & Commodities, Buildings & Infrastructure, Business Assurance, and Product Testing & Services. These are composed of 10 Product Lines, sharpening Bureau Veritas’ position as a focused and Product Line centric multi-specialist company. This structure concentrates capital and expertise where Bureau Veritas has the strongest right to win and enables clearer performance accountability.

New portfolio growth and adjusted operating margin distribution

 

REVENUE

ADJUSTED OPERATING MARGIN

 

Company

mix

Growth

Contribution

to growth

Range

 

Total revenue

2026e

Organic

CAGR 2023-2026e

Organic

2023-2026e

Based on estimates

2024-2025

Industrials & Commodities

c. 37%

c. 9.5%

c. 45%

15.0%-16.0%

Buildings & Infrastructure

c. 36%

c. 6.5%

c. 27%

13.0%-14.0%

Business Assurance

c. 10%

c. 9.0%

c. 10%

18.0%-19.0%

Product Testing & Services

c. 17%

c. 6.5%

c. 14%

21.0%-22.0%

Company post exit from activities planned for exit

100%

c. 7-8%

- 

 

Activities planned for exit

 

c. 0%

c. 4%

 

 

Performance: from Execute to Amplify

The Company's performance programs were developed and executed since 2024, focusing on functional scalability and operational leverage programs. These programs will deliver 110 basis points by the end of 2026. The full LEAP | 28 ambition is to deliver up to 180 basis points of improvement, half of which are expected to be reinvested to fund performance programs and growth.

Digital and AI will be key enablers of Bureau Veritas’ performance programs, helping automate low-value tasks, improve planning, and support experts in their work. By scaling digital operating systems, the Company aims to enhance productivity, service quality, and customer experience, while supporting margin improvement.

For 2027–2028, Bureau Veritas will amplify these programs: full global deployment of all performance programs, AI workflow integration, and redesigned service delivery models.

People: an Expert-First approach

Bureau Veritas People strategy aims at developing expertise in new economy skills, building leaders and enabling teams to work in a more tech-augmented way. To achieve this ambition, the Company introduced a Product Line-centric organization and has capability building programs for its People.

The first completed program is the Sustainability Graduate Program, and the subsequent one will aim at developing capabilities around digital assurance.

The Company is also accelerating tech-augmented ways of working, with AI upskilling programs already supporting broad adoption across the workforce. Together, these programs will help Bureau Veritas connect, develop and deploy expertise more effectively, increasing the impact of its people for customers and supporting long-term growth and performance.

AI AT BUREAU VERITAS

Bureau Veritas benefits from AI as both a growth catalyst and a transformation lever.

Its value proposition is evolving through new ways of working, with AI-enabled operating systems connecting proprietary data and technical expertise to improve productivity, service quality, and customer experience.

AI is a major accelerator of Bureau Veritas’ strategy, expanding growth opportunities in mission-critical assets and enabling new AI-related services. It opens new service opportunities in areas such as AI assurance, cyber, data integrity, and automated monitoring. This strengthens Bureau Veritas’ role as an independent trusted third party, helping clients address new risks around data, cyber, and responsible deployment.

Together, these opportunities support the ambition to generate EUR1 billion in AI-driven markets and services by 2030. This is to compare to c. EUR370 million baseline at the end of 2026 (including the full acquisition of LotusWorks).

Deep technical expertise and decades of accumulated proprietary data give Bureau Veritas a distinctive competitive foundation for AI. Governed by a single Company-wide framework, AI is already being deployed at scale, driving measurable productivity improvements and transforming service delivery in Certification and Inspection. Over time, this means a fundamentally higher-value proposition: data-driven, continuously integrated, and performance-centric services that go beyond the traditional inspection and certification model.

2028 FINANCIAL AMBITION – CONFIRMED

Bureau Veritas is building on three years of consistent execution to amplify its delivery in 2027-2028:

LEAP | 28 AMBITION (2024-2028)

CONFIRMED

STRONGER M&A COMPONENT

(2027–2028)

Mid to high-single digit

organic revenue growth

High-single digit

total revenue CAGR4

Confirmed

 

Upgraded to double-digit

Consistent

margin improvement4

Confirmed

Above 90%5

cash conversion

1x–2x

leverage

Strong

 

1.5x–2x

Double digit

shareholder returns, based on EPS

CAGR4 + dividend yield

Confirmed

 

A disciplined approach to capital allocation, driving superior returns

Bureau Veritas will maintain a disciplined capital allocation policy, supporting accelerated M&A and active portfolio management while preserving financial flexibility. Capex and dividend policies remain unchanged, and the leverage range is tightened from 1.0x–2.0x to 1.5x–2.0x net debt/EBITDA by 2028.

ASSUMPTIONS

Capex

c.2.5%-3.0% of Company revenue

M&A

Focus on bolt on and mid-sized strategic deals

Dividend

65% payout ratio of adjusted net income

Leverage

1.5x-2.0x net debt/EBITDA

ROIC6

Above 20.0%

 

This disciplined capital allocation framework is expected to sustain attractive returns through the cycle. Bureau Veritas targets ROIC6 above 20% by 2028, supported by adjusted operating margin ramp-up, portfolio high-grading and continued financial discipline.

CAPITAL MARKETS DAY 2026 MATERIALS

› Date: Tuesday September 22, 2026
› The presentation slides and all supporting materials will be available from 9:00 a.m. CET at: https://group.bureauveritas.com/capital-markets-day-2026
› A replay of the Capital Markets Day will be available on the same webpage following the event.

2026 & 2027 FINANCIAL CALENDAR

› Capital Markets Day: September 22, 2026
› Q3 2026 Revenue: October 21, 2026 (before market)
› FY 2026 Results: February 25, 2027 (before market)
› Q1 2027 Revenue: April 22, 2027 (before market)
› H1 2027 Results: July 27, 2027 (before market)
› Q3 2027 Revenue: October 21, 2027 (before market)

ABOUT BUREAU VERITAS

Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the Company innovates to help them navigate change.

Created in 1828, Bureau Veritas’ 82,000 employees deliver services in 140 countries. The Company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.

Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.

For more information, visit www.bureauveritas.com, and follow us on LinkedIn.

Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.

This press release (including the appendices) contains forward-looking statements, which are based on current plans and forecasts of Bureau Veritas’ management. Such forward-looking statements are by their nature subject to a number of important risk and uncertainty factors such as those described in the Universal Registration Document (“Document d’enregistrement universel”) filed by Bureau Veritas with the French Financial Markets Authority (“AMF”) that could cause actual results to differ from the plans, objectives and expectations expressed in such forward-looking statements. These forward-looking statements speak only as of the date on which they are made, and Bureau Veritas undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, according to applicable regulations.

____________________

1 At constant currency

2 Based on published FY2024, FY2025 financial statements and the guidance 2026

3 Based on 2026 consensus estimates

4 At constant currency

5 (Net cash generated from operating activities - lease payments + income tax) / adjusted operating profit

6 After-tax Adjusted Operating Profit / (Equity excluding assets & liabilities held for sale + Net Debt excluding lease)

 

 

 

Contacts

ANALYST/INVESTOR CONTACTS

Laurent Brunelle
+33 (0) 7 79 52 69 21
laurent.brunelle@bureauveritas.com

Colin Verbrugghe
+33 (0) 6 80 53 26 72
colin.verbrugghe@bureauveritas.com

Romain Gorge
romain.gorge@bureauveritas.com

Inès Lagoutte
ines.lagoutte@bureauveritas.com

MEDIA CONTACTS

Karine Havas
+33 (0) 6 68 63 83 18
karine.havas@bureauveritas.com

Frédéric Vallois
+33 (0) 6 21 66 31 04
frederic.vallois@bureauveritas.com

反对 0
举报 0
收藏 0
打赏 0
评论 0
一线黑色素瘤新选择:西达本胺联合纳武利尤单抗全球III期临床降低27%疾病进展风险
联合治疗组与纳武利尤单抗组mPFS的HR为0.73,差异具有统计学显著性和临床意义,肩并肩优于同线方案的历史研究数据。联合方案有望为黑色素瘤患者提供一种不同于双免疫治疗、安全性可预测的新选择。 脑转移是黑色素瘤最主要致死原因。此前于ESMO 2025年会公布的开放队列研究显示,西达本胺联合方案在这一人群中展现积极疗效信号。 微芯生物合作方HUYABIO拟向FDA更新数据,并接洽商业合作伙伴。 西班牙马德里--(美国商业资讯)-- 2026年欧洲肿瘤内科学会(ESMO)年会正于西班牙马...

0评论2026-10-271657

Galderma’s Relfydess (relabotulinumtoxinA) Receives Approval in China for Frown Lines
The Chinese National Medical Products Administration (NMPA) has approved Relfydess, the first and only ready-to-use liquid neuromodulator designed with PEARL Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines...

0评论2026-10-271321

拉斯海玛酋长为首家拉斯海玛在华商务咨询机构揭幕,深化与广东的合作
中国广州--(美国商业资讯)--阿联酋联邦最高委员会成员、拉斯海玛酋长谢赫·萨乌德·本·萨克尔·卡西米殿下为该酋长国首家驻华商务咨询公司揭幕,开启双方合作的新篇章。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20261021003496/zh-CN/ 该机构位于工业重镇广州,将作为拉斯海玛对接中国企业的重要平台,推动双方在重点领域拓展合作。 此次揭...

0评论2026-10-271759

Mundipharma宣布,ReSPECT III期临床试验的补充研究结果已在2026 年IDWeek 会议上作为最新突破性研究口头报告进行展示
仅限贸易及医疗媒体 英国剑桥--(美国商业资讯)-- Mundipharma今日公布了全球ReSPECT III期临床试验的补充研究结果。该试验旨在评估 REZZAYO® (醋酸雷扎芬净)在接受异基因造血干细胞移植(allo-HSCT)的成人患者中预防侵袭性真菌病(IFD)的疗效。上述III期试验数据已于今日作为最新突破性研究口头报告,在IDWeek 2026大会上正式展示。 该报告在此前(2026年4月)公布的ReSPECT试验主要结果基础之上,补充了更多细节数据,包括进一步的终...

0评论2026-10-271272

Energy Impact Partners深化与新加坡经济发展局合作,推动能源创新与脱碳
EIP与新加坡经济发展局(EDB)扩大合作,将EIP的全球网络与新加坡能源转型及脱碳生态系统相连接 该合作通过为高潜力企业打造在新加坡发展壮大的路径,支持新加坡的“脱碳重大挑战计划” 纽约和新加坡--(美国商业资讯)--全球能源投资机构Energy Impact Partners (EIP)与新加坡经济发展局(EDB)今日宣布深化合作伙伴关系,共同推动新加坡的能源创新与脱碳进程。该消息在首届2026年新加坡产业脱碳论坛上公布,该论坛由EDB、新加坡科技研究局(A*STAR)以及先进能源与...

0评论2026-10-271274

Brenus Pharma新型体内免疫疗法STC-1010在一线MSS型转移性结直肠癌中显示出安全性并激活T细胞,2例患者实现完全缓解
ESMO 2026上公布的BreAK CRC-001 Ia期研究:43%的患者最初均不可切除,治疗后转为符合手术条件 海报编号1023P – 开发性治疗学 马德里--(美国商业资讯)--临床阶段生物科技公司Brenus Pharma公布了BreAK CRC-001研究Ia期剂量递增试验的首批数据。共有9名不可切除患者接受治疗;其中89%伴有肝转移,89%为KRAS突变肿瘤,该人群通常对免疫治疗耐药。中位随访时间为8个月(范围1–14个月;数据截止日期为2026年8月6日)。 ...

0评论2026-10-271580

Lifezone Metals确认与Orion CMC就Kabanga镍矿项目开展的谈判已进入后期阶段
纽约--(美国商业资讯)-- Lifezone Metals Limited(纽约证券交易所代码:LZM)注意到,Orion Resource Partners创始人兼集团首席执行官Oskar Lewnowski今日在接受Bloomberg Television采访时,谈及本公司位于坦桑尼亚的Kabanga镍矿项目。 针对采访播出后媒体和投资者的问询,本公司确认,与Orion Critical Mineral Consortium(Orion CMC)就Kabanga镍矿项目一项大额股权...

0评论2026-10-271491

SBC Medical啟動DNA甲基化檢測研發,用於評估生物年齡
憑藉Waqoo Group的科研與技術生態,為主動健康管理與健康長壽建立全新個人基準 加州爾灣--(美國商業資訊)-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC)(簡稱「公司」或「SBC Medical」)是一家在多個醫療保健領域提供管理支援的醫療服務機構(MSO)。公司今日宣布,已啟動一項檢測技術的自主研發,旨在透過DNA甲基化分析評估個人生物年齡。 本新聞稿包含多媒體資訊。完整新聞稿請見此: https://www.bus...

0评论2026-10-262027

沙特海事与物流大会聚焦海事行业协同及沙特贸易投资增长机遇
沙特阿拉伯吉达--(美国商业资讯)--沙特海事与物流大会在吉达超级穹顶会展中心开幕,汇聚政府机构代表、海运与物流行业领袖及工商界人士,重点探讨沙特阿拉伯在保障贸易畅通、增强供应链韧性方面可发挥的作用。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20261022270299/zh-CN/ 当前,贸易和航运形势快速变化,促使企业重新评估运输路线、运营方案和投资选择。本届大会为各方提供交流平台,探讨合作机遇,加强...

0评论2026-10-261928

Tigo Energy TS4产品线全面兼容Fronius,为太阳能安装商带来更多配置选择
Tigo MLPE全面兼容Fronius多款逆变器系列,助力全球太阳能安装商灵活打造高品质、定制化的光伏系统。 洛斯加托斯,加利福尼亚州--(美国商业资讯)--智能太阳能与能源软件解决方案的领先供应商Tigo Energy, Inc.(NASDAQ: TYGO)(以下简称“Tigo”或“公司”)今日宣布,已获得 Fronius International GmbH出具的制造商兼容性声明,确认Tigo Flex MLPE产品与多款Fronius逆变...

0评论2026-10-261751